BrainStorm Deferring Shareholders Conference Call in Anticipation of Upcoming Developments

BrainStorm Deferring Shareholders Conference Call in Anticipation of Upcoming Developments

<0> BrainStorm Cell Therapeutics Inc. (OTC.QB:BCLI)Adrian Harel, Ph.D., CEO+972-3-9236384 </0>

BrainStorm Cell Therapeutics Inc. (OTC.QB: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced that it is deferring its shareholders conference call scheduled for December 11, 2012, in anticipation of significant positive company developments likely to be released shortly. The company will announce the re-scheduled conference call date as soon as senior management is authorized to discuss these developments.

BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of adult stem cell therapeutic products derived from autologous bone marrow cells and intended for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn™ technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel-Aviv University. For more information, visit the company’s website at .

Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.